XBiotech

XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Genmab - ADR

iShares Nasdaq Biotechnology ETF

Innoviva

Novavax

Trillium Therapeutics

Vanda Pharmaceuticals

Vertex Pharmaceuticals

These are the biotech stocks with the best value, fastest growth, and most momentum for Q3 2020.

Top Biotech Stocks for Q3 2020

Donors with Potent Natural Immunity Against the Virus are Identified as the Starting Point for XBiotech’s Drug Development Program to Treat COVID-19

XBiotech Identifies “Super Bloods” for the Development of a True Human™ COVID-19 Therapy

Kodiak Sciences Inc

TRI Pointe Group

These are the small cap stocks with the best value, fastest growth, and most momentum for May.

Top Small Cap Stocks for May 2020

DRDGOLD

Enphase Energy

iFresh

NantHealth

Orion Energy Systems

These exciting stocks to buy for aggressive investors might be small, but they have massive growth potential when the pandemic clears up. 
The post 7 Top Stocks to Buy for Aggressive Investors appeared first on InvestorPlace.

7 Top Stocks to Buy for Aggressive Investors

New antibody to block IL-1⍺ scheduled to enter clinical trials as next generation anti-inflammatory therapy in 2021 New antibody to block IL-1⍺ scheduled to enter clinical trials as next generation anti-inflammatory therapy in 2021

XBiotech Developing Novel True Human Antibody Targeting Interleukin-1alpha (IL-1⍺)

AUSTIN, Texas, April  03, 2020  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) and BioBridge Global today announced their collaboration to participate in a U.S. Food and Drug Administration (FDA) investigational program for U.S. blood centers to begin collecting and distributing convalescent plasma from individuals who have recovered from COVID-19.

XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients

AUSTIN, Texas, Feb.  19, 2020  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the final results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., New York City time, on February 12, 2020.

XBiotech Announces Final Results of Tender Offer

AUSTIN, Texas, Feb.  13, 2020  (GLOBE NEWSWIRE) -- This press release corrects a prior version published on February 13, 2020 and is updated to revise the preliminary proration factor.  The corrected press release reads:

Corrected Press Release: XBiotech Announces Preliminary Results of Tender Offer

The company's offer to buy back shares was overtendered, resulting in a prorated deal.

Why XBiotech Shares Are Tumbling 23.4% Today

AUSTIN, Texas, Feb.  13, 2020  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) today announced the preliminary results of its “modified Dutch auction” tender offer, which expired at 5:00 p.m., New York City time, on February 12, 2020.

XBiotech Announces Preliminary Results of Tender Offer

XBiotech Is Trading Below Its $30 Offer Price For Good Reason, But It Still Could Rise

The company is offering to buy back shares from investors at a big premium.

Why XBiotech Shares Are Skyrocketing 32.7% Today

AUSTIN, Texas, Jan.  14, 2020  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) announced today that it commenced a “modified Dutch auction” tender offer to purchase up to $420,000,000 of its common shares, or such lesser number of common shares as are properly tendered and not properly withdrawn, at a price not less than $30.00 nor greater than $33.00 per common share, to the seller in cash, less any applicable withholding taxes and without interest (the “Offer”). The Offer is made upon the terms and subject to the conditions described in the offer to purchase and in the related letter of transmittal. The closing price of XBiotech’s common shares on the NASDAQ Global Select Market on January 13, 2020, the last full trading day before the commencement of the Offer, was $18.62 per share. The Offer is scheduled to expire at 5:00 p.m., New York City time, on February 12, 2020, unless the Offer is extended.

XBiotech Commences Tender Offer to Purchase up to $420,000,000 of its Shares

Validation and Capital from Deal Enables XBiotech to Vigorously Advance anti-IL-1⍺ Antibody Program, Fuel Pipeline Validation and Capital from Deal Enables XBiotech to Vigorously Advance anti-IL-1⍺ Antibody Program, Fuel Pipeline

XBiotech Closes on Sale of True Human Antibody Bermekimab to Janssen

XBiotech Move To Out-Licence Next Generation Antibody Brings In Substantial Cash For Pipeline Expansion

AUSTIN, Texas, Dec.  17, 2019  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI). The addition to the NBI will become effective prior to market open on Monday, December 23, 2019.

XBiotech Added to NASDAQ Biotechnology Index

XBiotech announced a massive deal with Johnson & Johnson subsidiary Janssen, which is thrusting the overlooked biopharma onto the radars of investors.

This Small-Cap Biotech Gained as Much as 106.4% Today

ArQule

Thor Industries

Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some.

Why These 3 Biotechs More Than Doubled on Monday

XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen XBiotech will continue its True Human anti IL-1⍺ antibody discovery program outside of dermatology and use its manufacturing technology to produce clinical supplies of bermekimab for Janssen

XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen

Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Bermekimab in HS Enrollment Rate Exceeds Expectation, Suggesting High Unmet Need and Anticipation for Bermekimab in HS

XBiotech Announces Rapid Enrollment for its Randomized Multi-Center Clinical Study for Bermekimab in Patients with Hidradenitis Suppurativa

AUSTIN, Texas, Nov.  12, 2019  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) has enrolled the first patient in a randomized, double-blind, placebo-controlled Phase 2 clinical study to evaluate its IL-1a blocking antibody therapy in patients with moderate to severe Atopic Dermatitis (AD) (also known as Eczema). Chaired by award-winning dermatologist Seth B. Forman, MD, of ForCare Medical Group in Tampa, FL, the study will assess weekly bermekimab therapy to reduce inflammatory skin lesions, itch, and pain in patients suffering from eczema.

XBiotech Announces First Patient Enrolled in Placebo-Controlled Clinical Study Evaluating Its anti-IL-1⍺ Therapy Bermekimab in Patients with Atopic Dermatitis (Eczema)

AUSTIN, Texas, Oct.  23, 2019  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the first patient was enrolled in its randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating bermekimab in patients with moderate to severe Hidradenitis Suppurativa (HS). The multi-center, international study will enroll approximately 150 patients into three arms: two bermekimab dosing regimens versus a placebo arm over sixteen (16) weeks of therapy. The study is chaired by renowned investigative dermatologist Alice Gottlieb, MD, PhD, Medical Director of dermatology at the Mount Sinai Beth Israel Campus and Clinical Professor at the Icahn School of Medicine at Mount Sinai.

XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa

Bermekimab Blocks Key Inflammatory Pathway in Systemic Sclerosis, a Devastating Disease with Currently No Approved Therapies Bermekimab Blocks Key Inflammatory Pathway in Systemic Sclerosis, a Devastating Disease with Currently No Approved Therapies

XBiotech Announces First Patient in Clinical Study to Evaluate Bermekimab in Systemic Sclerosis

Results of the Company’s Phase 2 Trial to be Presented by Dr. Alice Gottlieb on Saturday, October 12, 2019 Results of the Company’s Phase 2 Trial to be Presented by Dr. Alice Gottlieb on Saturday, October 12, 2019

XBiotech Announces Oral Presentation of Atopic Dermatitis Results for Bermekimab at 2019 EADV Congress in Madrid, Spain

AUSTIN, Texas, Sept.  20, 2019  (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that the Canadian Patent Office has granted XBiotech a patent (Patent Number 56003542-6CA) covering the use of bermekimab in the treatment of inflammatory skin diseases. The patent describes studies showing that antibodies which specifically neutralize the activity of interleukin-1alpha (IL-1α), such as bermekimab, reduce skin inflammation and treat inflammatory skin diseases. XBiotech has conducted a number of clinical trials in dermatology using bermekimab, including studies in hidradenitis suppurativa, atopic dermatitis, and psoriasis vulgaris (plaque psoriasis). The company has also published clinical findings for the treatment of psoriasis and acne. The development of bermekimab for the treatment of inflammatory skin disorders is an important part of XBiotech’s commercialization programs.

News for XBiotech Stock (XBIT)